Radiotherapy Side Effect
112
35
40
29
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.7%
3 terminated out of 112 trials
90.6%
+4.0% vs benchmark
4%
5 trials in Phase 3/4
0%
0 of 29 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 29 completed trials
Clinical Trials (112)
Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung Cancer
ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer
Evaluation of Technological Innovation in Radiotherapy
Radiotherapy With Extreme Hypofractionation in Patients With Breast Cancer in Brazil: a Retrospective Cohort Study
Adaptive RadioTherapy for OroPharynx Cancer
Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies
Protons vs. Photons for High-risk Prostate Cancer
SMC Radiation Oncology Breast Cancer Cohort Study
Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.
CPAP or BiPAP for Motion Mitigation During Radiotherapy
Prospective RegIstry for Oncologic Reirradiation (PRIOR-DK)
Curatively Intended Thoracic Reirradiation
Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume
Early Diagnosis and Cardiovascular Risk Stratification in Children Exposed to Cancer Therapies
Preoperative Hypofractionated RT + Immunotherapy & Surgery for Retroperitoneal Sarcoma (FUSION-02)
DENTOFACIAL-PBT Stage 2 - Feasibility Study
RAdiotherapy With FDG-PET Guided Dose-PAINTing Compared With Standard Radiotherapy for Primary Head and Neck Cancer-3
Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-01)
MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)
Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)